<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846218</url>
  </required_header>
  <id_info>
    <org_study_id>AP-45WE</org_study_id>
    <nct_id>NCT04846218</nct_id>
  </id_info>
  <brief_title>Agonist Trigger With HCG Luteal Supplementation vs HCG Trigger With Progesterone Luteal Supplementation in Antagonist Controlled HyperstimulationCycle</brief_title>
  <official_title>Comparison Between Agonist Trigger With HCG Luteal Phase Supplementation vs HCG Trigger With Progesterone Luteal Phase Supplementation in Antagonist Controlled HyperstimulationCycle Regarding Clinical Pregnancy Rate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to compare agonist trigger and HCG luteal support vs standard&#xD;
      HCG trigger and progesterone luteal supplementation in antagonist controlled hyperstimulation&#xD;
      cycle as regards to clinical pregnancy rate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective Interventional randomized pilotstudy on patients undergoing controlled ovarian&#xD;
      hyperstimulation.&#xD;
&#xD;
      All patients will receive a fixed dose of 150-300 IU recombinant FSH (Gonal-F; Sereno&#xD;
      Laboratories,Madrid, Spain) for ovarian stimulation according to age, BMI and antral follicle&#xD;
      count (AFC).&#xD;
&#xD;
      After 6 days of stimulation, FSH will be adjusted according to ovarian response.&#xD;
&#xD;
      Premature LH surge will be prevented with 0.25 mg of a GnRH antagonist (Cetrotide; Serono&#xD;
      International, Geneva, Switzerland) starting on day 6 when two or more follicles reach a size&#xD;
      of 18-20 mm, trigger of ovulation will be done and followed by luteal phase support according&#xD;
      to the protocol assigned for each group.&#xD;
&#xD;
      Group 1:&#xD;
&#xD;
      A single dose of 0.2 mg triptorelin (Decapeptyl速 Ipsen Pharmaceutical Company, France) and&#xD;
      follow up with daily 125 IU HCG injections&#xD;
&#xD;
      Group 2:&#xD;
&#xD;
      A single dose of HCG 10000 IU was given followed by progesterone supplementation with 100mg&#xD;
      IM (Prontogest速).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">June 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>1 year</time_frame>
    <description>Clinical pregnancy diagnosed by pregnancy test and ultrasound</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>They will receive a single dose of 0.2 mg triptorelin (Decapeptyl速 Ipsen Pharmaceutical Company, France) and follow up with daily 125 IU HCG injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>They will receive a single dose of HCG 10000 IU was given followed by progesterone supplementation with 100mg IM (Prontogest速).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Prontogest</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Decapeptyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 20 and 39 years.&#xD;
&#xD;
          -  Body mass index between 18 and 30.&#xD;
&#xD;
          -  Unexplained infertility or male factor infertility&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Endocrinological disorder eg.:hyperprolactenemia, Hypo or hyper thyrodism&#xD;
&#xD;
          -  More than 2 previous attemptsof IVF&#xD;
&#xD;
          -  Any uterine anatomical anomaly.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AinShams Maternity Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>maii medhat nawara</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

